The Phase 3 study protocol is modified after IBT’s meeting with the FDA
Yesterday afternoon (EST) Infant Bacterial Therapeutics  had a meeting with the US Food and Drug Administration (FDA) in Washington DC to discuss the design of the company's clinical...
November 21, 2018
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2018
Message from the CEO   The third quarter was dominated by extensive preparatory work relating to the planned phase III study, called “The Connection Study”. In addition to chosing...
November 14, 2018
IBTs Chief Scientific Officer invited to speak at NEC Society Symposium 2019
Infant Bacterial Therapeutics (IBT) Chief Scientific Officer, Eamonn Connolly, PhD has been invited to speak and be a facilitator at the 2019 NEC Symposium in the session “Promising Novel...
November 9, 2018
Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2019
The Annual General Meeting of 2018 decided that the Nomination Committee would be appointed as follows: "The Chairman of the Board shall convene the three largest shareholders in the...
October 8, 2018
Infant Bacterial Therapeutics publishes prospectus in connection with the list change to Nasdaq Stockholm
On August 30, 2018, Infant Bacterial Therapeutics AB (publ) (”IBT” or the ”Company”) announced that Nasdaq Stockholm’s Listing Committee had approved the admission of the...
September 4, 2018
Infant Bacterial Therapeutics has been approved for listing on the main market of Nasdaq Stockholm
Nasdaq Stockholm’s Listing Committee has approved the admission of Infant Bacterial Therapeutics AB’s (“IBT” or the “Company”) shares of series B for trading on the main market of Nasdaq...
August 30, 2018
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2018
Message from the CEO   The second quarter was dominated by extensive preparatory work relating to the pivotal phase III study, called “The Connection Study”. Our experience from...
August 16, 2018
IBT plans to start its phase 3 study in the second half of 2018 and contracts CRO
IBT has previously announced its plan to start the phase 3 study in the first half of 2018. Preparations for the study have taken slightly longer than expected and the Company now plans to initiate...
June 26, 2018
Annual General Meeting of Infant Bacterial Therapeutics AB
The Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 15, 2018 voted to approve the following resolutions:   Adoption of the annual report Discharge...
May 15, 2018
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2018
Message from the CEO   During the past year, IBT passed the most important milestones in the company's history. The company's drug candidate, IBP-9414, which we believe will prevent...
May 15, 2018
Infant Bacterial Therapeutics AB Nomination Committee modifies its proposal to the Board of Directors
The IBT Nomination Committee presented its proposals to the AGM in April 2018, which will be held on May 15, 2018.   The Nomination Committee has subsequently been informed that...
May 9, 2018
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting on Tuesday, May 15, 2018 at 15.00 in the City Conference Ingenjörshuset, Malmskillnadsgatan 46,...
April 16, 2018
Infant Bacterial Therapeutics publishes Annual Report for 2017
Today, Infant Bacterial Therapeutics AB (publ) publishes the Annual Report for the financial year 2017. The report is available on IBT’s website under the section Financial Reports...
April 12, 2018
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2017
Message from the CEO  During the last year, IBT passed the most important milestones in the company’s history. The company’s pharmaceutical candidate, IBP-9414, for the prevention of...
February 28, 2018
Outcome of Infant Bacterial Therapeutics’ rights issue
To access the press release, please read the following disclaimer here.
February 2, 2018
New Project Manager at IBT
IBT welcomes Patrick Beke as Project Manager. Patrick has an education in biomedical science and oncology. He has experience in academic research and managerial experience in primary patient...
January 17, 2018
Prospectus relating to Infant Bacterial Therapeutics’ rights issue published
To access the press release, please read the following disclaimer here.
January 10, 2018
Extraordinary general meeting in Infant Bacterial Therapeutics
The extraordinary general meeting of Infant Bacterial Therapeutics AB (publ) (“IBT”) on 8 January 2018 resolved, among other things, to approve the board of directors’ resolution of...
January 8, 2018
Infant Bacterial Therapeutics presents data from its Safety and Tolerability Study in premature infants
Infant Bacterial Therapeutics and the principal investigator Dr. Josef Neu presented data today from its Safety and Tolerability study in premature infants at the ongoing Hot Topics in...
December 11, 2017
Notice of extraordinary general meeting in Infant Bacterial Therapeutics
The shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to an extraordinary general meeting on Monday 8 January 2018 at 10.00 am at Citykonferensen Ingenjörshuset,...
November 24, 2017
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2017
Message from the CEO IBT announced results from the safety and tolerability study of IBP-9414 on September 11th. The data demonstrate a similar safety and tolerability profile in the active...
November 23, 2017
Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2018
The Annual General Meeting of 2017 decided that the Nomination Committee would be appointed as follows: "The Chairman of the Board shall convene the three largest shareholders in the...
November 8, 2017
European Medicines Agency adopts a positive opinion on the Paediatric Investigation Plan for IBT’s lead product
The Paediatric Committee (PDCO) at the European Medicines Agency (EMA) has adopted a positive opinion on the Paediatric Investigation Plan (PIP) proposed by IBT for the development of...
September 28, 2017
Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups.
Infant Bacterial Therapeutics and the principal investigator Dr. Josef Neu have made an initial evaluation of the top line data of the Phase II “Randomized, double blind, parallel-group,...
September 11, 2017
Information from Infant Bacterial Therapeutics Capital Markets Day 2017
Infant Bacterial Therapeutics has today, September 8, 2017, hosted a Capital Markets Day for investors, financial analysts and media in Stockholm.   The purpose of the Capital...
September 8, 2017
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2017
Message from the CEO   IBT are currently in the completion stage of the phase II clinical trial (NCT02472769) and are concurrently working with preparations for a subsequent...
August 28, 2017
Invitation to Infant Bacterial Therapeutics AB (publ) Capital Markets Day
Infant Bacterial Therapeutics has the pleasure to invite investors, financial analysts and media to attend our Capital Markets Day in Stockholm on September 8, 2017 See the press release in both...
June 16, 2017
Annual General Meeting of Infant Bacterial Therapeutics AB (publ)
The Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2017 voted to approve the following resolutions:   Adoption of the annual report Discharge from...
May 4, 2017
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2017
Message from the CEO IBTs operations will during the current year be focused on completion of the ongoing Phase ll study and planning of the following clinical Phase lll study of IBP-9414. As...
May 4, 2017
Infant Bacterial Therapeutics AB (publ) Annual Report for 2016 has now been published
Infant Bacterial Therapeutics AB (publ) Annual Report 2016 is now available on the companies website www.ibtherapeutics.com.   A physical copy of the Annual Report can also be...
April 6, 2017
Annual General Meeting of Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting at 2:00 p.m. on Thursday, 4 May 2017, at Citykonferensen Ingenjörshuset, Malmskillnadsgatan 46,...
April 5, 2017
Infant Bacterial Therapeutics AB (publ), (IBT) has been approved for listing on Nasdaq First North’s Premier segment.
Infant Bacterial Therapeutics AB (publ) (“IBT”), today traded on Nasdaq First North, has applied and been approved for listing on Nasdaq First North’s Premier segment. Companies which are...
March 10, 2017
IBT to present at Bio-Europe Spring 2017
Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that develops drugs that meet the medical needs of premature infants, will present the company on Tuesday March 21, 2017...
March 1, 2017
Infant Bacterial Therapeutics AB (publ), (IBT) Interim report January 1 – December 31 2016
Message from the CEO “During the month of June, the first patients were recruited and dosed in IBTs clinical study, IBP-9414, in the USA.  The last patient was recruited on January 23, 2017...
February 14, 2017
Last patient enrolled in IBT’s Phase 2 study
Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the last premature infant has now been enrolled and recruitment to the Phase 2 study is now closed.   The Phase 2 study...
January 24, 2017
IBT Corporate Presentation at the 9th Biotech Showcase
Find here the Corporate Presentation CEO Staffan Strömberg is presenting at the 9th Biotech Showcase in San Francisco.   Download the PDF here
January 11, 2017
IBT to present at 9th Annual Biotech Showcase 2017
Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that develops drugs that meet the medical needs of premature infants, will present the company on Wednesday...
December 15, 2016
IBT adds new indication for Gastroschisis-Related Intestinal Dysfunction
Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that develops drugs that meet the medical needs of premature infants, is in the early planning stages of developing a...
December 14, 2016
Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study
IBT announces that the second and last planned evaluation of safety data by the independent Data Safety Monitoring Board (DSMB), in the ongoing Phase II clinical study, was performed on...
November 21, 2016
Infant Bacterial Therapeutics AB appoints new CFO
Infant Bacterial Therapeutics AB (publ.) (“IBT”) is pleased to announce the appointment of Daniel Mackey as Chief Financial Officer (CFO) from January 2017 replacing Michael Owens in this role....
October 12, 2016
IBT welcomes new Business Analyst
IBT welcomes Crescent Yingyue Liao as Business Analyst. Crescent holds a Bachelor's degree in Biochemistry and a Master's degree in Bioentrepreneurship.   Read more IBT team here
September 2, 2016
Infant Bacterial Therapeutics AB (publ), (IBT) Interim report January 1 – June 30 2016
Message from the CEO “In June we announced that the first premature infant had been enrolled and dosed in the Company´s Phase ll clinical trial. This Phase ll trial is a randomized,...
August 19, 2016
New Vice President Clinical Development at IBT
IBT is welcoming Agneta Heierson as Vice President Clinical Development. She has over 25 years of experience working in the pharmaceutical industry. Most recently she has been the Global...
August 16, 2016
Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial
Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the first premature infant has been enrolled and dosed in the Company´s Phase 2 clinical trial. This Phase 2 trial is a...
June 7, 2016
IBT’s rights issue fully subscribed
The result of Infant Bacterial Therapeutics AB’s (“IBT” or the “Company”) rights issue, for which the subscription period ended on 23 May 2016, indicates that 3,575,583 shares,...
May 26, 2016
Prospectus relating to IBT’s rights issue published
To access the press release, please read the following disclaimer here.
April 27, 2016
IBT announces fully underwritten SEK 100 million rights issue
To access the press release, please read the following disclaimer here.
April 27, 2016
IBT receives Rare Pediatric Disease Designation from FDA for drug candidate
Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the U.S. Food and Drug Administration (FDA) has awarded IBT Rare Pediatric Disease Designation for its drug candidate IBP-9414,...
March 31, 2016
First day of trading of IBT B shares on NASDAQ First North
Today IBT rang the NASDAQ bell to start the first day of trading of IBT B shares on NASDAQ First North. Actual share information from Nasdaq OMX Stockholm here.
March 29, 2016
Infant Bacterial Therapeutics is listed on Nasdaq First North and publishes company description
Infant Bacterial Therapeutics AB (publ) (“IBT”) has been approved for listing and the company’s series B shares will be traded on Nasdaq First North as from 29 March 2016 with Erik Penser...
March 21, 2016
IBT welcomes a new Head of Pharmaceutical Development and Manufacturing
IBT is glad to welcome in its team Paul Alhadeff as Head of Pharmaceutical Development and Manufacturing. From today, Paul will lead IBT CMC team. He brings great knowledge from his past experience...
March 14, 2016
Proposal for distribution and separate listing of Infant Bacterial Therapeutics from BioGaia
The board of directors of parent company BioGaia AB (publ) has resolved to propose to an Extraordinary General Meeting in BioGaia on 18 March 2016 to distribute the shares in the subsidiary Infant...
February 19, 2016
IBT welcome new a Project Coordinator
IBT welcomes Jin-Yu Lu as Project Coordinator in Pharmaceutical Development. Jin has education in life science and bioentrepreneurship. She has experience in administrative and operational support...
January 21, 2016
IBT has U.S. IND open and Swedish CTA approved for clinical study
IBT announces today that the IND (Investigational New Drug) for the prevention of necrotizing enterocolitis (NEC), has been accepted by the FDA (U.S. Food and Drug Administration). Furthermore, IBT...
January 8, 2016
New CFO at IBT
Michael Owens has joined IBT as Chief Financial Officer. Michael has a background as Auditor at Arthur Andersen & Co. and Ernst & Young AB. He has held the position as CFO at Vitamex AB and...
December 4, 2015
IBT has relocated to a new office
Come visit us at our new office at Bryggargatan 10, 111 21 Stockholm, Sweden.
October 1, 2015
New addition to IBT Board of Directors
Margareta Hagman, M.B.A, was elected to the Board of Directors in the beginning of September. Margareta is working as CFO and Executive Vice President at BioGaia AB. Margareta has been at BioGaia...
September 24, 2015
IBT receives a further SEK 35 million funding from BioGaia
To support Infant Bacterial Therapeutics efforts to develop a drug to prevent the fatal disease necrotizing enterocolitis, BioGaia’s board of directors has resolved to invest a further SEK 35...
September 7, 2015
IBT receives additional funding from BioGaia
Infant Bacterial Therapeutics plans to start a study on the safety and tolerability of the product in 2015. To allow for the study start, BioGaia will support IBT with an additional investment of 520...
March 26, 2015
Orphan Drug Designation in Europe
Infant Bacterial Therapeutics has now obtained the Orphan Drug Designation for Lactobacillus reuteri for the prevention of necrotizing enterocolitis in Europe. Read the official press release here
February 23, 2015
New Head of Clinical Operations at IBT
Infant Bacterial Therapeutics is glad to welcome Tina Lorentzon as Head of Clinical Operations. Tina brings her extensive and rich experience in management of clinical trials within the...
February 2, 2015
New CCO at IBT
Sanjiv Sharma is joining Infant Bacterial Therapeutics as the new Chief Commercial Officer. Sanjiv brings to Infant Bacterial Therapeutics his long experience of launching companies and optimizing...
November 7, 2014
New CTO at IBT
Infant Bacterial Therapeutics is appointing Anders Kronström as Chief Technical Officer. Anders brings to the company significant experience from the pharmaceutical industry and will strengthen the...
October 20, 2014
New CMO at IBT
Infant Bacterial Therapeutics is welcoming Erik Kinnman as Chief Medical Officer. Erik will contribute with his extensive knowledge and experience from the pharmaceutical industry to the on-going...
August 22, 2014
New board member at IBT
Anders Ekblom is the latest addition to the Board of directors at Infant Bacterial Therapeutics. Anders has extensive experience as an executive and leader with broad business knowledge from senior...
April 11, 2014
FDA approves orphan drug designation
Necrotizing enterocolitis (NEC) is a rare and extremely severe disease that affects premature infants. The FDA Office of Orphan Product Development has approved the request. Read the official press...
February 21, 2014
BioGaia invests in a drug against NEC
The board of BioGaia has decided to invest in the first phase of a long-term project aimed at developing a drug with rigorous hygiene, analysis and documentation requirements, to treat the highly...
February 21, 2014